Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million

▤ Summary

Palisade Bio announced an agreement with accredited investors to exercise existing warrants and raise about $3.9 million in gross proceeds. The company will issue replacement warrants as part of the transaction and expects to use the net proceeds for working capital and general corporate purposes. The securities involved are restricted to accredited investors and the company plans to file a resale registration statement with the SEC. Palisade Bio is a clinical-stage biopharmaceutical company focused on autoimmune, inflammatory, and fibrotic disease therapeutics.

$ Funding

▦ Linked Companies